EGFR and schizophrenia: Tadmor et al. (2018) tested another quinazoline ErbB inhibitor, JNJ28871063, and reported that this inhibitor ameliorates the phencyclidine (PCP)-induced decrease in social interaction, which is implicated in the negative symptoms of schizophrenia [164].